trending Market Intelligence /marketintelligence/en/news-insights/trending/chaq7rrszcyfw5vgshpipg2 content esgSubNav
In This List

Cytori Therapeutics implements 1-for-10 reverse stock split

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cytori Therapeutics implements 1-for-10 reverse stock split

Cytori Therapeutics Inc. said May 23 that it implemented a 1-for-10 reverse stock split.

The split reduced the San Diego cell therapy developer's outstanding stock to about 6.2 million shares from about 61.6 million shares. Fractional shares were rounded up to the nearest whole share.

Cytori Therapeutics expects the split to enable it to regain compliance with the Nasdaq Stock Market's bid price listing requirement.